GlassScriptPhysician profile
Richard W Vail
NPI 1013932359
$3,350.76
in general payments reported to CMS, 2019-2025
33 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $101 · 2021: $341 · 2022: $592 · 2023: $1,064 · 2024: $741 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $455.27 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $427.62 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $312.67 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.97 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $238.94 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $199.13 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $145.72 | 2023-2025 | O-Arm, Intellis Adaptivestim |
| Exact Sciences Corporation | $143.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $129.31 | 2021-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $124.92 | 2023-2024 | Veozah |
| Pfizer INC. | $70.11 | 2023-2025 | |
| Antares Pharma, INC. | $68.64 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Corium, LLC | $67.04 | 2022-2023 | Azstarys |
| Glaxosmithkline, LLC. | $63.10 | 2023-2024 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $51.13 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $48.22 | 2021 | |
| Eyevance Pharmaceuticals LLC | $48.22 | 2021 | |
| Merck Sharp & Dohme LLC | $45.33 | 2025 | Lagevrio, Gardasil 9, Capvaxive |
| Abbott Laboratories | $45.07 | 2022-2024 | Proclaim |
| Novartis Pharmaceuticals Corporation | $41.22 | 2019-2021 | |
| Genentech USA, INC. | $39.32 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $37.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.18 | 2022 | |
| Inari Medical, INC. | $31.15 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Halozyme INC | $30.66 | 2023 | |
| Esperion Therapeutics, INC. | $29.83 | 2021-2023 | Nexletol |
| Vertex Pharmaceuticals Incorporated | $25.76 | 2025 | |
| Medtronic USA, INC. | $21.81 | 2019 | |
| Edwards Lifesciences Corporation | $19.90 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Tolmar, INC. | $16.07 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.52 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.44 | 2022 | |
| Gt Medical Technologies, INC | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Vail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.